A Study of CM310 in Subjects With Moderate to Severe Asthma
Status:
Not yet recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
This study is a multi-center, randomized, double-blind, placebo-controlled Phase II clinical
study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of
CM310 in subjects with moderate to severe asthma.
The study consists of three periods, including an up to 4-week screening period, a 24-week
randomized treatment period, and a 8-week safety follow-up period.